cloud based digital signage singapore

Wellteq Signs Global Agreement to Supply Digital Wellness Services to Fortune 500 US Bank Northern Trust Corporation

  • Wellteq (CSE.WTEQ) (OTCQB.WTEQF) has signed a 5-year global Master Services Agreement (MSA) to supply digital wellness services to Northern Trust Corporation (NASDAQ.NTRS) employees.
  • Northern Trust, a Fortune 500 company and leading financial services provider with more than 20,000 employees globally, is set to initiate delivery of the WellteQ Digital Health platform to employees within the Asia-Pacific region.
  • The first stage of deployment commences in Q3 2021 for employees in Singapore, Hong Kong, Australia, and the Philippines.

WellteQ Digital Health Inc. (CSE.WTEQ) (OTCQB.WTEQF) (the "Company" or "Wellteq") is pleased to announce the Company has signed a global Master Services Agreement for 5 years with Northern Trust Corporation, a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, families, and individuals.

Companies invest into preventative or corrective health services for their workforces to improve employee health, workplace culture and team engagement and to reduce employee related costs such as absenteeism and preventable healthcare risk, preventable care utilization, and related care expenditures. A 2010 study published by Harvard University: Health Affairs estimated that, for every dollar spent on corporate wellness programs, medical costs fell by approximately $3.27 and absenteeism costs fell by about $2.73 for every dollar spent. 1 With such quantifiable benefits, the industry is projected to grow to over US $90 billion annually by the end of 2026. 2

Through its smartphone application, Wellteq offers personalized wellness, risk reduction, illness prevention and digital coaching capabilities to employees in over 30 countries and 12 languages. Wellteq's capabilities are seamlessly integrated with wearables, such as Garmin (NASDAQ.GRMN), Apple Watch (NASDAQ.AAPL) and Fitbit (NASDAQ.GOOGL), and with rewards, incentives and telemedicine partners.

As a banking institution with offices across the United States and 23 locations in Canada, Europe, the Middle East, and the Asia-Pacific region, Northern Trust has recognized the importance of offering localized employee wellness solutions to their regional teams. The first wave of the Wellteq deployment offers Wellteq's digital health platform to Northern Trust's Asia Pacific employees in Singapore, Hong Kong, Australia and the Philippines commencing in Q3, 2021.

Wellteq CEO Scott Montgomery stated, "Wellbeing is more essential than ever. While employees try to cope with drastic and rapid workplace changes and professional stresses, employers need to find new tools to help support employees. A recent survey from the Centers for Disease Control and Prevention found that 41% of all U.S. adults are struggling with mental health 3 stemming from the COVID-19 pandemic. Wellteq's behaviour change support programs offer credible health information and digital coaching across sleep, activity, mindset and nutritional habits and we're working with forward-thinking organizations like Northern Trust that genuinely care to help their teams survive and thrive in this new normal."

"We are deeply committed in supporting our employees and encourage holistic wellbeing," said Angelo Calvitto, Head of Asia Pacific, Northern Trust. "Wellteq complements the extensive suite of benefits and resources we provide our employees and will help bring them the most relevant resources to boost their physical, emotional, and financial health while at work and at home."

About Wellteq

Wellteq Digital Health Inc. is a leading provider of personalized digital health and wellness solutions across the Continuum of Care. To learn more, visit https://www.wellteq.co .

About Northern Trust

Northern Trust Corporation (NASDAQ.NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 22 U.S. states and Washington, D.C., and across 23 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2021, Northern Trust had assets under custody/administration of US$14.8 trillion, and assets under management of US$1.4 trillion. For more than 130 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Please visit our website or follow us on Twitter . Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Please read our global and regulatory information .

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. These statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

These statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date.

The CSE has neither approved nor disapproved the contents of this news release.


1 Harvard University: Health Affairs. "Workplace Wellness Programs Can Generate Savings." February 2010.

2 MarketsandMarkets Research Private Ltd. "Corporate Wellness Solutions Market Worth $94.6 billion by 2026 – Exclusive Report by MarketsandMarkets." June 2021.

3 Mark É. Czeisler et al. "Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24–30, 2020," Morbidity and Mortality Weekly Report, August 14, 2020; Volume 69, Number 32, pp. 1049–57, cdc.gov.

Glen Akselrod
Bristol Investor Relations
glen@bristolir.com
T: (905) 326-1888 ext 1

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×